| Project Title  | Funding   | Strategic Plan Objective | Institution                                   |
|--|-----------|--------------------------|---|
| Treatment of Medical Conditions among Individuals with Autism Spectrum Disorders   | \$496,547 | Q2.S.E                   | National Institutes of Health                 |
| Refining the Tourette Syndrome phenotype across diagnoses to aid gene discovery  | \$413,188 | Q2.Other                 | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO       |
| Early Life Seizures Disrupt Critical Period Plasticity   | \$409,568 | Q2.S.E                   | UNIVERSITY OF PENNSYLVANIA                    |
| Molecular mechanisms linking early life seizures, autism and intellectual disabil  | \$326,289 | Q2.S.E                   | University of Colorado, Denver                |
| Platform for autism treatments from exome analysis   | \$289,389 | Q2.S.E                   | Rockefeller University                        |
| Genetic Modifiers of Seizure Disorders in Fragile X Syndrome   | \$261,539 | Q2.S.D                   | Emory University                              |
| Self-Regulation and Sleep in Children At Risk for Autism Spectrum Disorders  | \$244,724 | Q2.S.E                   | PURDUE UNIVERSITY                             |
| Translating OCD GWAS findings into mice: identifying epistatic modifiers of BTBD3  | \$237,000 | Q2.S.E                   | UNIVERSITY OF CHICAGO                         |
| Neuroendocrine Regulation of Metabolism and<br>Neurocognition  | \$211,825 | Q2.S.E                   | National Institutes of Health                 |
| Autism Spectrum Disorders and Depression: Shared Mechanisms in Brain and Behavior  | \$160,115 | Q2.S.E                   | Vanderbilt University                         |
| Characterization of the sleep phenotype in adolescents and adults with autism spectrum disorder                              | \$150,000 | Q2.S.E                   | Vanderbilt University                         |
| Molecular analysis of gene-environment interactions in the intestines of children with autism                                | \$150,000 | Q2.S.E                   | Columbia University                           |
| Neuroactive Steroid GABAA Receptor Positive<br>Modulators for Fragile X Syndrome   | \$62,748  | Q2.S.D                   | SAGE THERAPEUTICS, INC.                       |
| Direct recording from autism brains  | \$60,074  | Q2.S.E                   | California Institute of Technology            |
| Identifying a blood-based biomarker for Autism<br>Spectrum Disorder-related inflammatory bowel disease                       | \$60,000  | Q2.S.E                   | Wake Forest University                        |
| Testing the ribosomal protein S6 as treatment target and biomarker in autism spectrum disorders                              | \$59,995  | Q2.S.D                   | Cincinnati Children's Hospital Medical Center |
| Mapping the Neurobehavioral Phenotype in Phelan McDermid Syndrome  | \$35,000  | Q2.S.D                   | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI       |
| Relationship Between Subtypes of Restricted and<br>Repetitive Behaviors and Sleep Disturbance in Autism<br>Spectrum Disorder | \$27,552  | Q2.S.E                   | Vanderbilt University                         |
| Early Life Seizures Disrupt Critical Period Plasticity   | \$2,237   | Q2.S.E                   | UNIVERSITY OF PENNSYLVANIA                    |
| PRECURSORS TO THE DEVELOPMENT OF ANXIETY DISORDERS IN YOUNG CHILDREN WITH AUTISM SPECTRUM DISORDER                           | \$0       | Q2.S.E                   | University of North Carolina                  |
| PRECURSORS TO THE DEVELOPMENT OF ANXIETY DISORDERS IN YOUNG CHILDREN WITH AUTISM SPECTRUM DISORDER                           | \$0       | Q2.S.E                   | Duke University                               |
| AUTISM AND OBESITY: CO-OCCURRING CONDITIONS OR DRUG SIDE EFFECTS?  | \$0       | Q2.S.E                   | Children's Mercy Hospital                     |
| Role of astrocytic glutamate transporter GLT1 in Fragile X   | \$0       | Q2.S.D                   | Tufts University                              |

| Project Title  | Funding | Strategic Plan Objective | Institution                           |
|--|---------|--------------------------|---------------------------------------|
| Single-unit recordings in neurosurgical patients with autism                                       | \$0     | Q2.S.E                   | California Institute of Technology    |
| CIRCADIAN RHYTHMS IN CHILDREN WITH ASD AND THEIR INFANT SIBLINGS                                   | \$0     | Q2.S.E                   | Naval Medical Research Center         |
| PRECURSORS TO THE DEVELOPMENT OF ANXIETY DISORDERS IN YOUNG CHILDREN WITH AUTISM SPECTRUM DISORDER | \$0     | Q2.S.E                   | Duke University                       |
| IMAGING DEPRESSION IN ADULTS WITH ASD  | \$0     | Q2.S.E                   | State University New York Stony Brook |